Drugmakers race to bring new cholesterol drugs to US market
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
REGENERON Pharmaceuticals Inc and Sanofi may get a head start on their biggest competitor in bringing a new class of cholesterol drugs to the US market.
The US Food and Drug Administration (FDA) has until July 24 to make a decision on the companies' application to market their jointly developed drug alirocumab, Regeneron and Sanofi said in a statement.
Share with us your feedback on BT's products and services
TRENDING NOW
Singaporeans can now buy record amount of yen per Singdollar
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
StarHub hands Ensign InfoSecurity control back to Temasek in S$115 million deal, books S$200 million gain
